Milestone
Neuraxpharm and Minoryx announced European Commission marketing authorisation for NEZGLYAL for cerebral adrenoleukodystrophy.
NEZGLYAL (leriglitazone) EU marketing authorisation
SEP 25, 2026
Every public signal F4 has attached to this firm, with sources and cross-entity links.
NEZGLYAL (leriglitazone) EU marketing authorisation